Spero Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company that develops novel therapies to treat bacterial infections, raised $30m in Series B funding.
Backers included existing investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group and Partners Innovation Fund.
Led by Ankit Mahadevia, M.D., President and Chief Executive Officer, Spero develops a pipeline of novel treatments for bacterial infections. The company’s pipeline of agents, focused on Gram-negative bacterial infections and Gram-positive and negative bacteria, fungi and protists, is based on an entirely new therapeutic platform called the “Potentiator”.
Spero intends to use the funds to further progress its therapeutic Potentiator Platform as well as to advance efforts in support of its DHFR program which targets Gram-positive and negative bacteria, fungi and protists.
The DHFR program seeks to expand a novel antifolate’s antibacterial spectrum to treat trimethoprim-resistant isolates including key Gram-negative pathogens.